HCPCS code J0834 – Cosyntropin injection

Key takeaways

HCPCS Code J0834 covers cosyntropin injection, 0.25 mg, and one billing unit equals one 0.25 mg vial.

J0833 was a not-otherwise-specified 0.25 mg cosyntropin code, deleted January 1, 2019, so J0834 is the code to report.

The NDC in 11-digit format with the N4 qualifier is required by Medicaid and many commercial payers.

The most common denial triggers are a missing or unsupported ICD-10 diagnosis code, an omitted NDC, and billing the deleted code J0833.

Pabau, the practice management platform we build, supports insurance billing and electronic claims through its claims management tools.

HCPCS Code J0834: Official descriptor and drug details

HCPCS Code J0834 is the HCPCS Level II code for injection, cosyntropin, 0.25 mg. CMS’s JW and JZ modifier code list prints the official descriptor as Injection, cosyntropin, 0.25 mg. One unit equals one 0.25 mg dose, which is the standard vial size for the rapid ACTH stimulation test. The Centers for Medicare and Medicaid Services maintains this HCPCS Level II drug code set.

Cosyntropin is a synthetic analogue of adrenocorticotropic hormone (ACTH). It stimulates the adrenal cortex to produce cortisol, making it the agent of choice for diagnosing adrenal insufficiency. The brand name is Cortrosyn, manufactured by Amphastar Pharmaceuticals. The generic is also available from other suppliers.

Clinical indications: When is cosyntropin administered?

Cosyntropin is administered primarily to diagnose primary and secondary adrenal insufficiency through the rapid ACTH stimulation test. The test measures serum cortisol before the injection and at 30 and 60 minutes after. A peak cortisol below 18-20 mcg/dL generally indicates adrenal insufficiency, so verify the exact threshold against your payer’s LCD.

The cortisol draws are lab work billed on their own claim lines, and the panel for this test is CPT 80400. The CRH stimulation test for Cushing’s syndrome is a separate workup, and its drug billed under corticorelin code J0795 until December 31, 2025.

FDA-approved indications include evaluation of adrenocortical function and diagnosis of adrenal insufficiency. Clinicians also use cosyntropin to evaluate the hypothalamic-pituitary-adrenal (HPA) axis after steroid withdrawal and to screen for congenital adrenal hyperplasia.

• Primary adrenal insufficiency (Addison’s disease): Absent or blunted cortisol response despite adequate ACTH stimulation
• Secondary adrenal insufficiency: Blunted cortisol response due to insufficient pituitary ACTH secretion
• Congenital adrenal hyperplasia (CAH): Elevated 17-hydroxyprogesterone response post-stimulation
• Hypopituitarism: Evaluation of residual adrenal reserve following pituitary surgery or radiation
• Post-steroid withdrawal: HPA axis recovery assessment after prolonged corticosteroid therapy

Billing units, dosage, and how to report J0834 on a claim

One unit of HCPCS Code J0834 equals one 0.25 mg dose of cosyntropin. Because the standard cosyntropin vial contains exactly 0.25 mg, one vial equals one unit in almost every clinical scenario. Bill one unit per injection unless the administering clinician documents a clinical reason for a different quantity.

A J0834 claim needs several fields beyond the code itself, and the same pattern holds across payers. The diagram after the list shows how the lines fit together on one claim.

1. Field 24D: Enter J0834 as the procedure code
2. Units: Enter 1 (for one 0.25 mg vial)
3. Place of Service: POS 11 for physician office; POS 22 for outpatient hospital
4. NDC line: Report the 11-digit NDC with the N4 qualifier and the unit of measure (ML or UN). Payers set whether it goes in the narrative field or on a separate line item
5. Diagnosis pointer: Link to the supported ICD-10-CM code in Field 21
6. Administration CPT: Bill CPT 96372 (IM or SC injection) or CPT 96374 (IV push) on the same claim, because J0834 covers the drug only

NDC reporting requirements for J0834

Medicaid requires an 11-digit NDC for every drug claim, and many commercial payers impose the same requirement. On the claim, the NDC takes the N4 qualifier, then the 11-digit number, then a unit of measure qualifier (ML for milliliters, UN for units). Do not use the NDC as printed on the vial label without reformatting. Drug manufacturers print NDCs in a 10-digit hyphenated format, so you zero-pad the correct segment to reach 11 digits.

Verify the exact NDC from the cosyntropin package labeling you dispensed from, since different manufacturers and lot presentations carry different NDCs. Never copy an NDC from a reference guide. Transcribe it from the vial used in that encounter.

Supported ICD-10-CM diagnosis codes for J0834

Medical necessity for HCPCS Code J0834 must be established by an ICD-10-CM diagnosis code that directly supports the clinical use of cosyntropin. The codes below are the most commonly accepted diagnoses, and you can check each one in our full ICD-10-CM code library. Local Coverage Determinations (LCDs) from your Medicare Administrative Contractor (MAC) may specify a narrower or broader list.

Always verify the final code selection against your MAC’s LCD for adrenal function testing. Using E27.40 on a claim where the payer’s LCD requires a more specific code is a common medical necessity denial trigger.

J0833 is deleted: use J0834

J0833 was the HCPCS code for injection, cosyntropin, not otherwise specified, 0.25 mg. It was deleted effective January 1, 2019, and J0834 is the active code for cosyntropin. Both codes used the same 0.25 mg unit, so only the code on the claim changes.

A claim that uses the deleted code J0833 on a current date of service will reject, so bill J0834. Check charge masters, superbill templates and saved order sets for the old code, because a stale template keeps resubmitting it.

Medicare and payer reimbursement for HCPCS Code J0834

Medicare Part B reimburses J0834 under the Average Sales Price (ASP) methodology. For non-facility settings (POS 11, physician office), the standard payment rate is ASP plus 6%. For facility settings (POS 22, outpatient hospital), payment runs through the Hospital Outpatient Prospective Payment System (OPPS). Depending on its current packaging status, cosyntropin may be separately payable or packaged into the APC rate.

CMS updates ASP-based drug payment rates quarterly. Never rely on a static figure from a reference guide. Before quoting a reimbursement amount, verify the current allowable in the CMS Physician Fee Schedule lookup tool and the quarterly ASP Drug Pricing file.

Place-of-service selection directly affects the payment rate, so confirm that the POS code matches where the drug was physically administered.

Prior authorization requirements for injectable drugs

Traditional Medicare generally does not require prior authorization for J0834. However, Medicare Advantage plans and many commercial payers impose their own PA requirements, and these vary significantly by plan. Never assume Medicare’s traditional policy applies to a Medicare Advantage patient.

• Step 1: Check the payer’s online portal or call the provider line before administering cosyntropin to a Medicare Advantage or commercial patient
• Step 2: If PA is required, submit clinical documentation including the clinical indication, relevant labs, and the supporting ICD-10 code
• Step 3: Record the PA reference number in the patient chart and on the claim
• Step 4: For urgent clinical situations, document medical necessity clearly; most payers permit retrospective PA review for emergent administration

Billing for drug wastage with HCPCS Code J0834

Cosyntropin comes in a 0.25 mg per 1 mL single-dose vial. Because one vial equals one billing unit, wastage arises only when part of the vial goes unused. A full 0.25 mg dose given as intended leaves no wastage to report. When partial use or vial loss does occur, two modifiers govern how to report it on a Medicare claim.

The JW modifier identifies the unused portion of a single-dose vial that is discarded in accordance with FDA labeling. With the JW modifier, the administered amount goes on the primary J0834 line. The discarded amount goes on a separate J0834 line with JW appended. The JW line does not change the total payment but documents that the disposal was legitimate and compliant.

The JZ modifier, introduced by CMS effective January 1, 2023, is an attestation that there was zero wastage from the vial. If the entire 0.25 mg was administered and nothing was discarded, append the JZ modifier to the J0834 line. This modifier eliminates the need to file a separate JW line and simplifies the claim while still satisfying CMS documentation requirements.

Can J0834 be billed with an E/M visit on the same day?

Yes, J0834 can be billed with an Evaluation and Management (E/M) code on the same date of service. The E/M visit must be a separately identifiable medical service beyond the drug administration itself.

Three codes typically appear on the same J0834 claim. First, J0834 covers the cosyntropin drug. Second, an administration code covers the act of injecting it: CPT 96372 for an intramuscular or subcutaneous injection, or CPT 96374 for an intravenous push. Third, an E/M code with Modifier 25 covers the separate clinical evaluation, if one was provided.

• J0834: The cosyntropin drug itself
• CPT 96372 or 96374: The injection administration service (separately billable)
• E/M + Modifier 25: A distinct evaluation visit beyond the administration (requires documentation of a separate, medically necessary encounter)

The documentation in the medical record must support all three services as distinct. A chart note that describes only the stimulation test protocol will not support the E/M code, even with Modifier 25 appended. It needs a separate clinical decision-making encounter.

Common J0834 claim denial reasons and how to fix them

J0834 denials cluster around a predictable set of documentation and coding errors. Effective denial management for this code starts with catching these before submission.

When appealing a denied J0834 claim, attach the physician order and the pre-stimulation and post-stimulation cortisol results. Add the drug administration record showing the vial NDC and dose, plus the clinical note documenting the indication. A complete clean claim submission with all supporting documentation reduces the appeal burden significantly.

Documentation requirements to support cosyntropin injection billing

Every J0834 claim needs a corresponding medical record that answers six core questions a payer auditor will ask. Missing any one of these elements is enough to trigger a medical necessity denial or a post-payment audit request.

• Clinical indication: Why was the ACTH stimulation test ordered? The chart must name the suspected or confirmed diagnosis
• Drug details: Drug name (cosyntropin or Cortrosyn), dose (0.25 mg), route (IV or IM), and date of administration
• Administering clinician: Name and credentials of the person who administered the injection
• NDC on the vial: The actual NDC from the vial used, confirmed at the time of administration
• Lab results: Pre-stimulation cortisol (baseline) and post-stimulation cortisol at 30 minutes and/or 60 minutes
• Medical necessity statement: A sentence in the encounter note connecting the diagnosis to the need for cosyntropin testing

Good medical billing compliance processes tie documentation capture directly to claim creation. The chart then supports every line the claim bills.

How claims management software keeps J0834 claims clean

Without a connected system, the drug line, the NDC and the administration code get rekeyed from the chart after the visit. Each rekeyed field is another chance to submit a deleted code or a mismatched NDC.

Pabau supports insurance billing through its claims management tools. In the US, claims go out electronically through Claim.MD as CMS-1500/837P claims, and eligibility checks and ERA remittances come back into the same system.

Prior authorization is tracked on the patient’s case, with the auth code, dates and sessions recorded and a warning when one is missing. Stock carries a batch number and an expiry date, both recorded against the patient and the appointment. The vial behind each cosyntropin claim stays on file.

Manage drug billing and claim submissions from one place

Pabau’s claims management supports insurance billing and electronic claims, so practices can submit cosyntropin claims from the system that holds the patient record.

Book a demo

Conclusion

J0834 is simple to code and easy to deny. The code carries one unit per 0.25 mg vial, and J0833 is no longer an option. Denials come from the claim around it: a missing NDC, an unsupported diagnosis, or a deleted code left in a charge template.

Search your charge master for J0833 this week and replace it with J0834. Then make the vial NDC and a linked ICD-10 code required before a cosyntropin claim leaves the practice.

Pabau keeps insurance billing and electronic claims in the same system as the patient record. Book a demo to see how it handles cosyntropin drug claims for endocrinology and internal medicine practices.

Continue your research

Need a full picture of how claims move from encounter to payment? Medical billing fundamentals explains the end-to-end claims workflow for physician practices.

Seeing repeat claim rejections across your drug codes? Denial management in healthcare covers systematic approaches to reducing and appealing claim denials.

Want to submit J-code claims through a clearinghouse? Medical claims clearinghouses explains how clearinghouses validate and route drug claims before they reach the payer.

Frequently asked questions